Analysed CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) News Sources
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
08-03-2026
marketbeat.com
Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
01-04-2026
yahoo.com
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
14-04-2026
yahoo.com
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
15-04-2026
marketbeat.com
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
28-04-2026
yahoo.com
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
28-04-2026
yahoo.com
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
07-05-2026
yahoo.com
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
14-05-2026
yahoo.com
What is the current price of CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ)?
The current price of CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) is $1.22.
CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) since the previous trading day is $-0.06.
CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) since the previous trading day is -4.6875%.
What is the most recent average sentiment score for CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ)?
The most recent average sentiment score for CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ)?
The most recent sentiment for CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ) is .
SEC-8K** Filing Available For CARDIOL THERAPEUTICS INC-A (CRDL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.